PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Dienogest - Endometriosis

PAD Profile : Dienogest - Endometriosis

Keywords :
Fibroids
Brand Names Include :
Zalkya, Dimetrum

Traffic Light Status

Status 1 of 1.

Status :
Blue
Important
Formulations :
  • Not Specified
Important Information :
To be initiated and first 6 months treatment to be supplied by a specialist
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 July 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agreed dienogest as a treatment option, after the optimisation of other hormonal treatments, for the management of endometriosis and associated pain symptoms.

Dienogest will be given a BLUE (with information sheet) traffic light status.  NOTE added in January 2025, treatment to be initiated and first 6 months treatment to be supplied by a specialist.

Associated BNF Codes

06. Endocrine System
06.04.01. Female sex hormones and their modulators
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More